Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTI164 in Rett Syndrome
NCT06621043Phase 2Completed
- Sponsor
- Fenix Innovation Group
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NTI164 in Rett syndrome (RTT), sponsored by Fenix Innovation Group. Primary endpoint: Rett Syndrome Symptom Index Score at 16 weeks. Started Sep 2023; status: completed.
02
Drugs
NTI164
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT06621043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06621043.